Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 2/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 8/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930701 | 0.88 | DRD2 (0.59) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL6258542 | 0.83 | DRD2 (0.68) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL18015780 | 0.81 | DRD2 (0.61) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL8046070 | 0.81 | DRD2 (0.56) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL9911006 | 0.81 | DRD2 (0.56) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL23654620 | 0.81 | DRD2 (0.56) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL11712752 | 0.79 | ATM (0.55) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL18014693 | 0.79 | DRD2 (0.59) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL11626646 | 0.79 | DRD2 (0.50) | DRD2DRD4OPRM1DRD3CYP2D6 | |
| SCHEMBL2087472 | 0.77 | DRD2 (0.56) | DRD2DRD4OPRM1DRD3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052495-B1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3052495-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049616-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-7601734-B2 | Such as methyl 5-(3,4-dihydro[1]benzofuro[3,2-c]pyridine-2(1H)-yl)-2,2-bis(4-fluorophenyl)pentanoate, having potent inhibitory effect on binding of alpha 2C-adrenoceptor; depression, anxiety, schizophrenia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070244145-A1 | Cyclic Amine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1757605-A1 | CYCLIC AMINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1219294-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-1997024325-A1 | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-07-10 | — | — | WO | disclosed |
| US-5302595-A | Muscarinic receptor antagonists | PFIZER INC. (US) | 1994-04-12 | — | — | US | disclosed |
| US-5219871-A | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0364123-B1 | MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 1991-06-12 | — | — | EP | disclosed |
| EP-0364123-A1 | Muscarinic receptor antagonists | Pfizer Limited (GB) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | DRD2 3538/4885DRD4 4063/4885OPRM1 2280/4885 |
| US-20070244145-A1 | Cyclic Amine Compound | ADRA2C, ADRB2, NR2C2 | DRD2 69/4885DRD4 244/4885OPRM1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.